Samuel Chackalamannil – Comprehensive Medicinal Chemistry (2017)

Описание

Previous editions of Comprehensive Medicinal Chemistry, published in 1990 and 2006, provided an integrated
reference source that encompassed all major aspects of drug discovery research. The third edition follows this
tradition and considerably expands its scope and content.
The trailblazing scientific discoveries of the 21st century have brought new opportunities for drug discovery
research. The discipline of medicinal chemistry continues to evolve as it adapts to these new opportunities and
strives to solve new challenges. Covered in the new edition are not only the breakthrough therapies of the past
decade in cancer, hepatitis C, heart failure, dyslipidemia, cystic fibrosis, multiple sclerosis, HIV, etc., but also
extensive discussion of new business models in drug discovery research, shifting industry demographics,
emerging technologies, in silico drug discovery tools, experimental ADME and toxicology, and biologics
medicine. The tone of this edition is prospective in which contributors identify outstanding issues and paths
forward in their area of expertise. The aim is to provide drug discovery scientists in industry, government,
academia, and research organizations with a contemporary global perspective on the field that includes a look
ahead in selected areas.
The eight individual volumes fulfill these objectives and include extensive discussion of biomolecular
therapeutics, drug targeting and delivery, development of chemical biology tools, data collection and
analysis, in silico models as predictors for biological properties, identification/validation of new targets,
approaches to quantify target engagement, new methods for synthesis of drug candidates such as green
chemistry, development of novel scaffolds for drug discovery, and the role of regulatory agencies in drug
discovery.
The individual volume editors have done an outstanding job to identify topics and contributors to meet
these goals and we thank them for their hardwork and diligence. In volume 1, Ana Martinez and Carmen Gil
recruited an international group of contributors who provide chapters on the emerging role of organizations
other than traditional pharmaceutical companies in drug discovery, the evolving science of chemical biology,
and new organic chemistry contributions to the discipline. In volume 2, Helmut Buschmann, Norbert Handler,
and Andrea Wolkerstorfer have accomplished a seemingly impossible task and attracted world-leading experts
across the wide field of drug discovery enabling technologies, covering contemporary thinking in a wide range
of key disciplines that enable modern medicinal chemistry and drug discovery and development. The
computational enabling technologies are the focus of volume 3, in which Andy Davis and Colin Edge have
assembled chapters covering both ligand-based and protein structureebased advances as well as exciting new
methodologies and case studies exploiting these. Alan Wilson identified experts in the fields of pharmacokinetics
and toxicology who describe a wide range of contemporary advances in prediction and analysis of
pharmaceutical properties and drug safety in volume 4. In volume 5, Ian Collins, Louis Lombardo, and Will
Watkins have assembled leading experts to discuss high impact drug discovery accomplishments over the past
decade in cancer chemotherapeutics, immunology and inflammation, and infectious diseases therapeutic areas.
Ved Srivastava edited volume 6 on biologic medicines, a significant and rapidly evolving area where medicinal
chemistry plays an important role. The chapters in this volume provide timely information on not only proteinbased
drugs, such as monoclonal antibodies and therapeutic proteins, but also peptides and nucleic acidebased
therapeutics. Volume 7, edited by Adrian Hall, Santhosh Neelamkavil, and Rob Jones, presents a detailed
account of the major advances in CNS, metabolic, and cardiovascular fields over the past decade and the
promising new opportunities. Joerg Holenz edited volume 8 that presents case histories of successful drug
discovery and strategic differentiation that have resulted in commercialized drugs and candidates in advanced
clinical trials.
We are truly grateful to the publishing team at Elsevier that includes Gemma Tomalin, Rachel Gerlis,Marise
Willis, and Sean Simms for their assistance and support throughout the process. With their expertise, this
project became what we believe is a noteworthy and valuable resource for the discipline of medicinal
chemistry. We look forward to the response and feedback of our colleagues who will use this information in
their own work

Dr. Samuel Chackalamannil
Dr. Chackalamannil obtained his PhD in chemistry from Yale University in 1984 and subsequently
worked in drug discovery research at Schering-Plough Corporation and Merck Research Laboratories,
where he was a distinguished fellow when he left in 2011. Since then, he has been teaching at Ernest
Mario School of Pharmacy, Rutgers University, New Jersey.
Dr. Chackalamannil has significant accomplishments in the discovery of new medicines. He led the
discovery of vorapaxar (Zontivity
), an FDA-approved antiplatelet drug for the prevention of heart
attack and stroke. His group also discovered a PDE-5 inhibitor clinical candidate dasantafil and an
adenosine A2a antagonist clinical candidate for the treatment of Parkinson’s disease. Altogether, he
was responsible for the discovery of nine development candidates in cardiovascular, central nervous
system, and metabolic disease areas.
Dr. Chackalamannil is a coinventor of 62 allowed US patents and numerous patent applications
worldwide. He has published 81 peer-reviewed articles and has coauthored a book. He has also given
numerous lectures at international meetings and academic institutions.
Dr. Chackalamannil is a two-time recipient of the Thomas Alva Edison Award for Emerging Technology
Patent and a two-time recipient of the Presidential Award for Discovery at Schering-Plough
Research Institute. He has chaired several sessions at American Chemical Society national meetings and Gordon Research Conference on
Medicinal Chemistry and was an organizer for Chemistry as a Life Science Symposium.